Find Reports
Select Report Type
Reimbursement Review
Displaying 126 - 150 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| glofitamab | Columvi | glofitamab | Relapsed or refractory diffuse large B-cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete | PC0320-000 | |||
| sacituzumab govitecan | Trodelvy | sacituzumab govitecan | HR+, HER2− advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0323-000 | |||
| niraparib abiraterone acetate | Akeega | niraparib abiraterone acetate | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0326-000 | |||
| olaparib | Lynparza | olaparib | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | PC0319-000 | |||
| vutrisiran | Amvuttra | vutrisiran | Hereditary transthyretin mediated amyloidosis (hATTR amyloidosis) | Reimburse with clinical criteria and/or conditions | Complete | SR0801-000 | |||
| Unresectable Hepatocellular Ca... | Unresectable Hepatocellular Carcinoma | Complete | PH0036-000 | ||||||
| evinacumab | Evkeeza | evinacumab | Homozygous familial hypercholesterolemia (HoFH) | Reimburse with clinical criteria and/or conditions | Complete | SR0778-000 | |||
| eltrombopag | N/A | eltrombopag | Severe Aplastic Anemia (SAA) | Reimburse with clinical criteria and/or conditions | Complete | SX0777-000 | |||
| ibrutinib | Imbruvica | ibrutinib | Waldenström’s Macroglobulinemia | Reimburse with clinical criteria and/or conditions | Complete | PC0328-000 | |||
| calaspargase pegol | Asparlas | calaspargase pegol | Acute lymphoblastic leukemia (ALL) | Reimburse with clinical criteria and/or conditions | Complete | PC0321-000 | |||
| bevacizumab and lomustine | N/A | bevacizumab and lomustine | Recurrent glioblastoma multiform | Reimburse with clinical criteria and/or conditions | Complete | PX0318-000 | |||
| polatuzumab vedotin | Polivy | polatuzumab vedotin | Large B-cell lymphoma | Do not reimburse | Complete | PC0313-000 | |||
| upadacitinib | Rinvoq | upadacitinib | Crohns disease | Reimburse with clinical criteria and/or conditions | Complete | SR0775-000 | |||
| efgartigimod alfa | Vyvgart | efgartigimod alfa | Generalized myasthenia gravis (gMG) | Reimburse with clinical criteria and/or conditions | Complete | SR0782-000 | |||
| HR+ HER2- Breast Cancer and Tr... | HR+ HER2- Breast Cancer and Triple Negative Breast Cancer, with inclusion of HER2 Low Breast Cancer | Complete | PH0033-000 | ||||||
| andexanet alfa | Ondexxya | andexanet alfa | Reversal of FXa inhibitor anticoagulant effects | Do not reimburse | Complete | ST0772-000 | |||
| NSCLC without actionable oncog... | Non-Small Cell Lung Cancer | Completed | PH0015-000 | ||||||
| elexacaftor/tezacaftor/ivacaft... | Trikafta | elexacaftor/tezacaftor/ivacaftor and ivacaftor | Cystic fibrosis, F508del CFTR mutation, 2 years and older | Reimburse with clinical criteria and/or conditions | Complete | SR0776-000 | |||
| somapacitan | Sogroya | somapacitan | Growth Hormone Deficiency (GHD) | Reimburse with clinical criteria and/or conditions | Complete | SR0779-000 | |||
| mirikizumab | Omvoh | mirikizumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | SR0773-000 | |||
| cabozantinib | Cabometyx | cabozantinib | Advanced or metastatic renal cell carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0312-000 | |||
| durvalumab and tremelimumab | Imfinzi and Imjudo | durvalumab and tremelimumab | unresectable hepatocellular carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0308-000 | |||
| ibrutinib | Imbruvica | ibrutinib | Chronic lymphocytic leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | PC0317-000 | |||
| rivaroxaban | N/A | rivaroxaban | Venous thromboembolic events (VTE) | Reimburse with clinical criteria and/or conditions | Complete | SX0750-000 - SR0750-000 | |||
| axicabtagene ciloleucel | Yescarta | axicabtagene ciloleucel | Relapsed or refractory follicular lymphoma | Reimburse with clinical criteria and/or conditions | Complete | PG0314-000 |
Health Technology Review
Displaying 126 - 150 of 602
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 126 - 150 of 2138
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| crovalimab | Reimbursement Review | Active | SR0858-000 | ||||
| 2025 Watch List: Artificial Intelligence | The 2025 Watch List focuses on the use of artificial intelligence technologies in health care and the issues that may arise with the implementation of these technologies. | Horizon Scan | Roundup | Completed | ER0015-000 | ||
| danicopan | Reimbursement Review | Complete | SR0815-000 | ||||
| enfortumab vedotin | Reimbursement Review | Complete | PC0353-000 | ||||
| pembrolizumab | Reimbursement Review | Active | PC0377-000 | ||||
| Planning for the Introduction of New CT Services in Rural and Remote Communities in Canada | We conducted an informal survey among senior medical imaging decision-makers to determine the factors that influence planning for new CT services in rural and remote communities in Canada. | Health Technology Review | CMII Service | Completed | CM0032-000 | ||
| Virtual Remote Imaging Services: CT and MRI Scanning | Health Technology Review | CMII Service | Active | CM0017-000 | |||
| vorasidenib | Reimbursement Review | Pending | PC0407-000 | ||||
| dostarlimab | Reimbursement Review | Active | PC0381-000 | ||||
| momelotinib | Reimbursement Review | Active | PC0355-000 | ||||
| garadacimab | Reimbursement Review | Active | SR0860-000 | ||||
| Comparative Effectiveness of Real-Time Teleultrasound Versus In-Person Ultrasound | Health Technology Review | CMII Service | Completed | CM0024-000 | |||
| elexacaftor/tezacaftor/ivacaftor and ivacaftor | Reimbursement Review | Complete | SR0837-000 | ||||
| Non-small Cell Lung Cancer | Reimbursement Review | Provisional Funding Algorithm | Merged | PH0081-000 | |||
| NSCLC without actionable oncogenic alterations | Reimbursement Review | Provisional Funding Algorithm | Merged | PH0059-000 | |||
| guanfacine hydrochloride extended-release | Reimbursement Review | Pending | SX0755-000 | ||||
| The Cost-Effectiveness and Budget Impact of Tocilizumab for COVID-19 | Health Technology Review | Technology Review | Completed | HE0051-000 | |||
| The Cost-Effectiveness and Budget Impact of Remdesivir for Inpatient Treatment of COVID-19 | Health Technology Review | Technology Review | Completed | HE0050-000 | |||
| Dosing of Immune Checkpoint Inhibitors | Health Technology Review | Systematic Review | In Progress | RE0053-000 | |||
| The Cost-Effectiveness and Budget Impact of Nirmatrelvir-Ritonavir for COVID-19 | Health Technology Review | Technology Review | Completed | HE0048-000 | |||
| The Cost-Effectiveness and Budget Impact of Remdesivir for Outpatient Treatment of COVID-19 | Health Technology Review | Technology Review | Completed | HE0049-000 | |||
| pegcetacoplan | Reimbursement Review | Withdrawn | SR0810-000 | ||||
| Environmental Scan of Genetic and Genomic Biomarker Testing Assessment Frameworks, Processes, and Inventories in Cancer Care | Health Technology Review | Environmental Scan | Completed | CP0037-000 | |||
| ibrutinib | Reimbursement Review | Received | PX0380-000 | ||||
| alectinib | Reimbursement Review | Complete | PC0350-000 |
Provisional Funding Algorithm
Displaying 76 - 81 of 81